Andere Sprachen Equillium, Inc.

Aktien

A2N7B3

US29446K1060

EQ

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 16.05.2024			% 5 Tage	% 1. Jan.
1,54 ^USD	0,00 %		-14,44 %	+113,00 %

14.05.	Equillium, Inc. Equillium gibt bekannt, dass eine Zwischenrekrutierung für die Phase 3 EQUATOR-Studie mit Itolizumab bei akuter Transplantat-gegen-Wirt-Krankheit erreicht wurde	CI
09.05.	Equillium, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease	14.05.
Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease	14.05.
Earnings Flash (EQ) EQUILLIUM Reports Q1 Revenue $10.7M	09.05.
Equillium, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights	09.05.
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists	07.05.
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	03.04.
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis	01.04.
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	01.04.
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	26.03.
Equillium Swings to Q4 Loss As Revenue Falls	25.03.
Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
Equillium, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	25.03.
Earnings Flash (EQ) EQUILLIUM Reports Q4 Revenue $9.2M	25.03.
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights	25.03.
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference	25.03.
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference	22.03.
EQUILLIUM : 2024 INDUCEMENT PLAN - Form 8-K	08.03.
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 and EQ102 in Development for Alopecia Areata and Celiac Disease	22.12.
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease	21.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Equillium, Inc.

Aktien

A2N7B3

US29446K1060

EQ

Andere Sprachen

Filter